Arbutus Biopharma P/E Ratio

Arbutus Biopharma (ABUS) currently reports a P/E ratio of 5.34. That is below the Healthcare sector average of 19.01. Use the charts on this page to explore Arbutus Biopharma's P/E ratio history and peer comparisons.

Arbutus Biopharma's P/E ratio of 5.34 is lower than the Healthcare sector average of 19.01. That is roughly 71.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Arbutus Biopharma's market price to a fundamental measure such as earnings, sales, or book value. At 5.34, ABUS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 5.34, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.01. From there, open related valuation or income-statement pages for Arbutus Biopharma, and consider following ABUS for alerts when major investors trade the stock.

Arbutus Biopharma is classified in the Healthcare sector. On P/E ratio, it currently shows 5.34 versus a sector average near 19.01. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABUS with unrelated industries.